EMA says no new patients should be started on Esyma for uterine fibroids

EMA says no new patients should be started on Esyma for uterine fibroids

February 13 2018 Doctors should not initiate Esyma (ulipristal acetate) in women with uterine...

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

February 13 2018 The European Medicines Agency has issued new recommendations regarding use of...

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

February 12 2018 The European Medicines Agency has updated advice regarding the use of retinoids...

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

February 9 2018 The medicines regulator has issued a Drug Safety Update relating to mycophenolate...

Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

February 8 2018 Antibiotic resistance in children’s E. coli is high against many...

  • EMA says no new patients should be started on Esyma for uterine fibroids

    EMA says no new patients should be started on Esyma for uterine fibroids

    Tuesday, 13 February 2018 12:18
  • New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    Tuesday, 13 February 2018 12:11
  • EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    Monday, 12 February 2018 14:21
  • New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    Friday, 09 February 2018 15:01
  • Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

    Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

    Thursday, 08 February 2018 10:39

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

Statins imageAugust 3 2017

NICE has released a new Quality Standard listing atorvastatin “as the preferred statin to offer patients because it is both clinically and cost effective.”

The recommendation is made in QS5 relating to chronic kidney disease in adults. It makes quality statements about identification and monitoring, blood pressure control, and statins for people with CKD.

It expects health professionals to monitor the blood pressure of adults with CKD and be aware of the recommended ranges. They should also “help people keep their blood pressure within the recommended range, for example, by starting or adjusting treatment, or advising on lifestyle changes.”

Health professionals should “check whether adults with CKD are taking a statin, and discuss the risks and benefits of starting statin therapy if not.” Atorvastatin 20mg should be offered and the dose increased if an adequate response to treatment is not achieved and eGFR is 30 ml/min/1.73 m2 or more.

If the patient is not able to tolerate atorvastatin 20mg or reports adverse effects, the health professional should discuss alternative options such as stopping the statin or changing the dose or type of statin.

Professor Gillian Leng, deputy chief executive at NICE, said: “We know that a high number of people with long-term kidney problems will develop cardiovascular disease. This means they have an increased risk of suffering a fatal heart attack or stroke.

“It is important for healthcare professionals to speak to patients about their treatment options. The effectiveness of statins is now well proven, as is their long-term safety. They may appeal to a lot of people who are at risk.”

A new paper in the British Journal of General Practice has added to the call for greater uptake of statins. Researchers have looked at how the 2014 NICE cholesterol guidelines are being applied, in a cross-sectional study using a sample representative of the English population aged 30–84 years.

“Even with optimal risk factor levels, males of different ethnicities would exceed the 10% risk threshold between the ages of 60 and 70 years, and females would exceed the threshold between 65 and 75 years,” the researchers found. “Under the NICE guidelines, 11.8 million males and females (37% of the adults aged 30–84 years) would require statin therapy, most of them (9.8 million) for primary prevention. When analysed by age, 95% of males and 66% of females without CVD in ages 60–74 years.”

The British Heart Foundation points out that the study suggests that 6.3 million people are missing out on the potential benefits of statins.

Dr Mike Knapton, Associate Medical Director at the British Heart Foundation, commented: “There is no question that statins lower people’s risk of heart attack and stroke. This study suggests that an estimated 6.3 million people are missing out on the potential lifesaving benefits of statins. If these people were taking statins, we could not only potentially prevent 290, 000 heart attacks and strokes, but also reduce the burden of these events on both the NHS and people’s lives.”

Links:
NICE QS announcement                
NICE QS5              
P Ueda et al. ‘Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis’. BrJGenPract 31 July.  2017 
BHF comment 

Clinical News

  February 20 2018 A covert study of pharmacies has claimed that some pharmacies are failing to give adequate safety warnings when selling analgesics and cold remedies. The Consumer Association’s...
February 19 2018 Pharmacists should be receiving educational material this week on a new patient safety campaign from the Centre of Pharmacy Postgraduate Education. Resources have been mailed out ahead...